Last updated on January 2019

A Study of Vericiguat in Participants With Heart Failure With Reduced Ejection Fraction (HFrEF) (MK-1242-001)


Brief description of study

This is a randomized, placebo-controlled, parallel-group, multi-center, double-blind, event driven study of vericiguat (MK-1242) in participants with HFrEF. The primary hypothesis is vericiguat (MK-1242) is superior to placebo in increasing the time to first occurrence of the composite of cardiovascular (CV) death or heart failure (HF) hospitalization in participants with HFrEF.

Clinical Study Identifier: NCT02861534

Contact Investigators or Research Sites near you

Start Over

Toll Free Number

Call for Information (Investigational Site 2467)
Pembroke Pines, FL United States
1.05miles

Toll Free Number

Call for Information (Investigational Site 2589)
Hollywood, FL United States
6.72miles

Toll Free Number

Call for Information (Investigational Site 2435)
Fort Lauderdale, FL United States
9.45miles

Toll Free Number

Call for Information (Investigational Site 2746)
Hialeah, FL United States
9.85miles

Recruitment Status: Closed


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.